Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience

MLA

Noam Benyamini, et al. “Outcome of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients Treated with Polatuzumab Vedotin-Based Therapy: Real-Life Experience.” Leukemialymphoma, vol. 62, no. 1, Sept. 2020. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....aed7fd719426bd3d6751ddebcaf37b3a&authtype=sso&custid=ns315887.

APA

Noam Benyamini, Miri Zektser, Odit Gutwein, Nadav Sarid, Gilad Itchaki, Anatoly Nemets, Uri Abadi, Nagib Dally, Shimrit Harlev, Kalman Filanovsky, Elena Ribakovsky, Merav Leiba, Netanel A Horwitz, Ron Ram, Chava Perry, Ronit Gurion, Abraham Avigdor, Orit Sofer, Irit Avivi, … Yair Goldhecht. (2020). Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience. Leukemialymphoma, 62(1).

Chicago

Noam Benyamini, Miri Zektser, Odit Gutwein, Nadav Sarid, Gilad Itchaki, Anatoly Nemets, Uri Abadi, et al. 2020. “Outcome of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients Treated with Polatuzumab Vedotin-Based Therapy: Real-Life Experience.” Leukemialymphoma 62 (1). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....aed7fd719426bd3d6751ddebcaf37b3a&authtype=sso&custid=ns315887.